PROSPECTIVE EVALUATION OF EFFECTS OF BROAD-SPECTRUM ANTIBIOTICS ON GASTROINTESTINAL YEAST COLONIZATION OF HUMANS

被引:131
作者
SAMONIS, G
GIKAS, A
ANAISSIE, EJ
VRENZOS, G
MARAKI, S
TSELENTIS, Y
BODEY, GP
机构
[1] UNIV TEXAS,MD ANDERSON CANC CTR,DEPT MED SPECIALTIES,INFECT DIS SECT,HOUSTON,TX 77030
[2] UNIV CRETE,MICROBIOL LAB,IRAKLION,GREECE
[3] UNIV CRETE,DEPT MED ONCOL,IRAKLION,GREECE
关键词
D O I
10.1128/AAC.37.1.51
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
This study evaluated the effects of broad-spectrum antibiotics on the gastrointestinal (G.I.) yeast flora of humans and correlated the findings with those obtained from a mouse model of G.I. colonization by Candida albicans. We prospectively studied 46 adult cancer patients who received one of five broad-spectrum antibiotics (ceftriaxone, ceftazidime, ticarcillin-clavulanic acid, imipenem-cilastatin, and aztreonam) as therapy for infections. Quantitative examination of yeast colonization of stools was conducted at the baseline, at the end of antibiotic treatment, and 1 week after discontinuation of therapy. Antibiotics with anaerobic activity (ticarcillin-clavulanic acid) or high G.I. concentrations (ceftriaxone) caused a higher and more sustained increase in G.I. colonization by yeasts than did antibiotics with poor anaerobic activity (ceftazidime and aztreonam) or a low G.I. concentration (imipenem-cilastatin). These results were similar to those obtained with a mouse model of G.I. colonization by C. albicans that involved the same antibiotics. Hence, the mouse model may be useful for evaluation of yeast colonization of the human G.I. tract.
引用
收藏
页码:51 / 53
页数:3
相关论文
共 35 条
[1]  
ANAISSIE EJ, 1989, REV INFECT DIS, V3, P369
[2]  
BAR W, 1989, APMIS, V97, P705
[3]  
BODEY GP, 1990, SEMIN ONCOL, V17, P24
[4]  
BODEY GP, 1984, AM J MED, V77, P13
[5]  
CLEELAND R, 1984, AM J MED, V19, P414
[6]   SELECTIVE DECONTAMINATION OF THE DIGESTIVE-TRACT WITH AZTREONAM - A STUDY OF 10 HEALTHY-VOLUNTEERS [J].
DEVRIESHOSPERS, HG ;
WELLING, GW ;
SWABB, EA ;
VANDERWAAIJ, D .
JOURNAL OF INFECTIOUS DISEASES, 1984, 150 (05) :636-642
[7]  
DONOWITZ GR, 1988, NEW ENGL J MED, V318, P490
[8]  
DONOWITZ GR, 1990, PRINCIPLES PRACTICE, P246
[9]  
EDWARDS JE, 1990, PRINCIPLES PRACTICE, P1943
[10]  
FREIREICH EMIL J., 1966, CANCER CHEMOTHERAP REP, V50, P219